Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 – Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents$4,995
- February - 2016
- In Pharmaceuticals
- By GBI Research 811 Views
Alzheimer’s Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain..
Total Pages: 144